CAR-NK cells

Phase 1Cell therapy

HHangzhou Cheetah Cell Therapeutics Co., Ltd

CAR-NK cells is one of 56 biologic programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

AutoimmuneRecruiting

Acute Myeloid LeukemiaPreclinical

Active, not recruiting

AutoimmunePhase 1

Recruiting

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

60 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

18 4

Vepesid

AAvyxa

Phase 3

52 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

32 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

30 8

Nexavar

Bayer

Phase 3

12 9

Cytoxan

BBaxter Healthcare Corporation

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Autoimmune

NCT06318533

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·HHangzhou Cheetah Cell Therapeutics Co., Ltd·N/A·NCT05247957·9 enrolled

Autoimmune1 trial

An Exploratory Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injections for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting·YYANRU WANG·Phase 1·NCT06318533·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CAR-NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Cheetah Cell Therapeutics Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHangzhou Cheetah Cell Therapeutics Co., Ltd

CAR-NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Autoimmune1 trial

References

Drug Info

Quick Facts

Related News